SCHEMBL3365374

SCHEMBL3365374

C#CCN(C)CCCCCCOc1ccc(N(C)S(=O)(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 13/20 0.56
PGR P06401 1/20 0.50
HPGD P15428 2/20 0.48
MAPK1 P28482 2/20 0.48
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
TSHR P16473 1/20 0.48
MAOA P21397 1/20 0.48
CYP2C19 P33261 1/20 0.48
THPO P40225 1/20 0.48
RAB9A P51151 1/20 0.48
HIF1A Q16665 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA4 P22748 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3365288 0.89 MAOB (0.56) MAOBMAOACA12CA1CA2
SCHEMBL3366909 0.89 MAOB (0.56) MAOBMAOACA12CA1CA2
SCHEMBL3362435 0.87 PGR (0.54) PGRRAB9AMAPTKMT2AL3MBTL1
SCHEMBL3365106 0.87 MAOB (0.53) MAOBMAOACA12CA1CA2
SCHEMBL3368626 0.86 PGR (0.53) PGRTSHRRAB9ACA12CA1
SCHEMBL3365352 0.86 PGR (0.53) PGRRAB9AMAPTKMT2AL3MBTL1
SCHEMBL3363565 0.85 PGR (0.57) PGRALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL3367242 0.85 PGR (0.52) PGRRAB9AMAPTKMT2AL3MBTL1
SCHEMBL3364591 0.85 PGR (0.52) PGRHPGDALDH1A1RAB9AMAPT
SCHEMBL3367719 0.83 LSS (0.52) PGRHPGDALDH1A1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1303503-B1 ANILINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-01-27 EP disclosed
US-6683201-B2 FOR THERAPY AND PROPHYLAXIS OF HYPERCHOLESTEROLEMIA, HYPERLIPEMIA, ARTERIOSCLEROSIS, VASCULAR DISEASES, MYCOSES, PARASITE INFECTIONS, GALLSTONES, TUMORS AND/OR HYPERPROLIFERATIVE DISORDERS, DIABETES HOFFMANN-LA ROCHE INC. 2004-01-27 US disclosed
CN-1443179-A Aniline derivatives HOFFMANN LA ROCHE (CH) 2003-09-17 CN disclosed
EP-1303503-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-04-23 EP disclosed
US-20020038025-A1 Analine derivatives as OSC inhibitors F.HOFFMANN-LA ROCHE AG (CH) 2002-03-28 US disclosed
WO-2002006189-A2 ANILINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020038025-A1 Analine derivatives as OSC inhibitors LSS, CYP51A1, CYP46A1 MAOB 2162/4885PGR 2421/4885HPGD 835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.